Trial Profile
A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of JNJ-53718678 in Children ≥28 Days and ≤3 Years of Age With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Rilematovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Acronyms CROCuS
- Sponsors Janssen; Janssen Pharmaceutical KK; Janssen Research & Development
- 13 Oct 2022 This trial has been completed in Bulgaria (End Date: 18 April 2022) according to European Clinical Trials Database record.
- 11 May 2022 Status changed from recruiting to discontinued.
- 08 May 2022 This trial has been completed in France, Hungary, Poland and Sweden, according to European Clinical Trials Database record.